

## ***Genetic-epidemiological component of "Genomics of Lipid-Associated Disorders" (GOLD)***

**Principal Investigator:** [Florian Kronenberg](#)

### **Background**

The prevalence of overweight and obesity is dramatically increasing. A large fraction of people is suffering from consequences of this "obese epidemic" which are mainly of cardiovascular nature. Among other factors, one underlying cause is dyslipidosis (disruption of fat metabolism), which leads to massive deposits of triglycerides in fatty tissue and of cholesterol in the arterial wall. The goal of this project is to discover and explain the function of each gene and protein involved in the process of uptake, storage and mobilization of lipids (fats) by cells.

### **Goal of GOLD**

GOLD is a consortium of researchers from various fields grown since 2002 and headed by our coordinator Rudolf Zechner from the University of Graz. Our group is responsible for the genetic-epidemiological component of the project that aims to identify genetic variation in candidate genes identified by structural and functional studies in other project components and to identify genetic variants that can be associated with phenotypes of interest.

The following projects are examples of our activities within GOLD.

[Genetic epidemiology of Adipose Triglyceride Lipase \(ATGL\)](#)


[Adiponutrin, lipoprotein metabolism and liver function](#)

[Genome-wide Association Studies](#)

## ***Genetic epidemiology of Adipose Triglyceride Lipase (ATGL)***

### **The influence of common variants with the *ATGL* gene**


With *ATGL* the first promising candidate gene identified within the GOLD consortium became available and our main focus shifted to its detailed investigation. We studied more than 2400 precisely phenotyped individuals from Utah including a group of 1120 patients with a BMI between 35 and 90 kg/m<sup>2</sup>. We sequenced the entire gene and its flanking regions in 48 morbid obese and 48 control subjects to find sequence variations. We identified further SNPs and an insertion/deletion polymorphism and selected 12 tagging SNPs which were finally genotyped in the 2400 patients and controls. Since *ATGL* is responsible for the initial step in the triacylglycerol catabolism releasing free fatty acids (FFA) into the circulation, we measured FFA as an intermediate phenotype. We observed clear associations between single SNPs as well as haplotypes of the *ATGL* gene with FFA levels (Figure 1) [1]. Our results are in line with functional studies of other consortium members including the finding that *ATGL* knock-out mice have lower FFA levels.



**Figure 1:** SNP association analysis showing differences in mean free fatty acid levels for those subjects with one copy and two copies of the minor allele compared to zero copies (wild-type). Results are shown for each of the 11 SNPs genotyped. The mean free fatty acid level of the entire population is 6.85 mg/dL. The presented p-values assume a trend per minor allele copy (additive inheritance model).


### The influence of rare variants within the ATGL gene

In order to assess the frequency and role of rare variants in a healthy population, we performed a mutation analysis of the full ATGL gene region in 1473 individuals of the healthy working SAPHIR population using an adapted pooled Ecotilling approach [2]. This revealed 55 novel, mostly rare (n=20) or private (n=34) variants and showed that even in a healthy working population rare variants are collectively frequent. Indeed, 7.7% of all individuals carried a rare variant and still 2.6% carried a rare missense variant.



**Figure 2:** Overview of the ATGL variants found in SAPHIR. This figure shows the localization of both novel and previously known ATGL variants superimposed to the gene structure. The upper part of the figure shows the 55 novel variants, while the lower part depicts previously known SNPs according to dbSNP build 131. Details about the meaning of the colour codes and arrow types are given in the legend within the figure. Nearly all genetic variants were rare (yellow boxes, n=20) or even private (red boxes, n=34). Image taken from reference [3].

Functional investigations by cell culture studies revealed a large spectrum of residual activity ranging from virtually wild-type activity to total loss of function (Figure 3). In order to evaluate the relevance of these in-vitro observations for the FFA levels in the population, we performed association studies and observed a trend towards lower FFA levels in rare variant carriers as well as an accumulation of rare variant carriers in the lower 10<sup>th</sup> percentile of the FFA distribution. However, and very surprisingly, the overall impact of these variants on the FFA levels was rather small despite the observed functional impairments.




**Figure 3:** Relative triglyceride hydrolase activities of the tested non-synonymous ATGL variants. Triglyceride hydrolase activities are given as relative to wild type ATGL after stimulation with murine GST-CG158 (ABHD5) and corrected for COS7 background activity (presented as mean ± standard deviation).

[\[top\]](#)

## Adiponutrin, lipoprotein metabolism and liver function

Adiponutrin (*PNPLA3*) is a predominantly liver-expressed transmembrane protein with phospholipase activity that is regulated by fasting and feeding. Recent genome-wide association studies identified *PNPLA3* to be associated with hepatic fat content and liver function, thus pointing to a possible involvement in the hepatic lipoprotein metabolism. Therefore, our group examined two common variants in this gene and parameters of lipoprotein metabolism in 23,274 participants from eight independent West-Eurasian study populations. We observed for the first time a strong additive association of a common nonsynonymous variant of adiponutrin (rs738409) with lipoprotein concentrations adjusted for age, gender, and alanine-aminotransferase: each copy of the minor allele significantly decreased levels of total cholesterol, non-HDL cholesterol, and LDL cholesterol levels (Figure 4). Our results suggest that adiponutrin is involved in the metabolism of apoB-containing lipoproteins [3]. Furthermore, we observed that genetic variants within this gene are associated with liver function [4].



**Figure 4:** Association of the SNP rs738409 of adiponutrin gene with apolipoprotein B-containing lipoproteins in 23,274 participants from eight independent West-Eurasian study populations.

[\[top\]](#)

## Genome-wide Association Studies

Our group is involved in several genome-wide association studies (GWAS), the most important of which is the GWA study on lipids. After carrying out a GWA study on HDL cholesterol [5], we and the field came to realize that very large sample sizes are required to have the statistical power to identify new genes and pathways involved in lipid metabolism. Therefore, we joined the European ENGAGE consortium with 16 population-based cohorts including up to 22,000 study participants. This initiative observed 22 genetic loci associated with serum lipid levels, 6 of which were newly identified. A score of risk alleles for lipids found associations of these alleles with carotid intima-media thickness as well as coronary heart disease incidence [6]. Since these 22 genetic loci still explained only up to 4.8% of lipid levels, we joined the "Global Lipids Genetics Consortium" with far more than 100,000 individuals investigated. This study finally identified 95 (59 new) genetic loci associated with serum lipid levels. These mapped variants explained 10-12% of each trait which corresponds to about a quarter of the variance for each trait expected to be explained by genes. Many of these genes were not previously implicated in lipoprotein metabolism and they

contribute not only to normal variation in lipid traits but also to extreme lipid phenotypes and lipid traits in multiple ethnic populations [7].

Further GWAS studies investigated phenotypes such as adiponectin plasma concentrations [8] or a large number of metabolic traits derived from metabolomic analyses [9,10.] For details, see project "[Genome-wide association studies](#)".

### Team members:

Stefan Coassin, Barbara Kollerits, Claudia Lamina, Anita Kloss-Brandstätter, Veit Schoenborn, Margot Haun, Gertraud Erhart, Arno Lingenhel

### Main collaborators:

- Rudolf Zechner, Robert Zimmermann, Martina Schweiger, (University of Graz)
- Iris M. Heid (University of Regensburg)
- Bernhard Paulweber (Paracelsus Private Medical University Salzburg)
- Steven C. Hunt, Ted Adams (University of Utah, USA)
- H.-Erich Wichmann, Thomas Illig, Norman Klopp, Annette Peters, Angela Döring, Konstantin Strauch, Christian Gieger, Karsten Suhre (Helmholtz Center Munich, D)
- KORA Study Group, SAPHIR Study, Utah Obesity Case-Control Study, Bruneck Study, CoLaus Study, SHIP Study, ERF Study, MICROS Study, Rotterdam Study

### Selected Publications:

1. [Schoenborn V\\*](#), [Heid IM\\*](#), [Vollmert C\\*](#), [Lingenhel A](#), Adams TD, Hopkins PN, Illig T, Zimmermann R, Zechner R, Hunt SC, [Kronenberg F](#): The ATGL gene is associated with free fatty acids, triglycerides and type 2 diabetes. *Diabetes* 55:1270-1275, 2006. [\[Pub-Med\]](#)
2. [Coassin S](#), Schweiger M, [Kloss-Brandstätter A](#), [Lamina C](#), [Haun M](#), [Erhart G](#), Paulweber B, Rahman Y, Olpin S, Wolinski H, Cornaciu I, Zechner R, Zimmermann R, [Kronenberg F](#): Investigation and functional characterization of rare genetic variants in the adipose triglyceride lipase in a large healthy working population. *PLoS Genetics* 6:e1001239, 2010. [\[Pub-Med\]](#)
3. [Kollerits B](#), [Coassin S](#), Beckmann ND, Teumer A, Kiechl S, Döring A, Kavousi M, Hunt SC, [Lamina C](#), Paulweber B, Kutalik Z, Nauck M, Van Duijn CM, Heid IM, Willeit J, [Brandstätter A](#), Adams TD, Mooser V, Aulchenko YS, Völzke H, [Kronenberg F](#): Genetic evidence for a role of adiponutrin in the metabolism of apolipoprotein B-containing lipoproteins. *Human Molecular Genetics* 18:4669-4676, 2009. [\[Pub-Med\]](#)
4. [Kollerits B](#), [Coassin S](#), Kiechl S, Hunt SC, Paulweber B, Willeit J, [Brandstätter A](#), [Lamina C](#), Adams TD, [Kronenberg F](#): A common variant in the adiponutrin gene influences liver enzyme levels. *Journal of Medical Genetics* 47:116-119, 2010. [\[Pub-Med\]](#)
5. Heid IM, [Boes E](#), Müller AM, [Kollerits B](#), Lamina C, [Coassin S](#), Gieger C, Döring A, Klopp N, Frikke-Schmidt R, Tybjaerg-Hansen A, [Brandstätter A](#), Luchner A, Meitinger T, Wichmann HE, [Kronenberg F](#): Genome-wide association analysis of high-density lipoprotein cholesterol in the population-based KORA Study sheds new light on intergenic regions. *Circulation: Cardiovascular Genetics* 1:10-20, 2008. [\[Pub-Med\]](#)
6. Aulchenko YS, Ripatti S, Lindquist I, Boomsma D, Heid IM, Pramstaller PP, Penninx BWJH, Janssens ACJW, Wilson JF, Spector T, Martin NG, Pedersen NL, Kyvik KO, Kaprio J, Hofman A, Freimer NB, Jarvelin MR, Gyllensten U, Campbell H, Rudan I, Johansson A, Marroni F, Hayward C, Vitart V, Jonasson I, Pattaro C, Wright A, Hastie N, Pichler I, Hicks A, Falchi M, Willemsen G, Hottenga JJ, de

Geus EJC, Montgomery GW, Whitfield J, Magnusson P, Saharinen J, Perola M, Silander K, Isaacs A, Sijbrands EJG, Uitterlinden AG, Witteman JCM, Oostra BA, Elliott P, Ruukonen A, Sabatti C, Gieger C, Meitinger T, Kronenberg F, Döring A, Wichmann HE, Smit JH, McCarthy MI, van Duijn CM, Peltonen L, for the ENGAGE consortium: Loci influencing lipid levels and coronary heart disease risk in 16 European population cohorts. *Nature Genetics* 41:47-55, 2009. [\[Pub-Med\]](#)

7. Teslovich TM, Musunuru K, Smith AV, Edmondson AC, Stylianou IM, Koseki M, Pirruccello JP, Ripatti S, Chasman DI, Willer CJ, Johansen CT, Fouchier SW, Isaacs A, Peloso GM, Barbalic M, Ricketts SL, Bis JC, Aulchenko YS, Thorleifsson G, Feitosa MF, Chambers J, Orho-Melander M, Melander O, Johnson T, Li X, Guo X, Li M, Shin CY, Jin GM, Jin KY, Lee JY, Park T, Kim K, Sim X, Twee-Hee OR, Croteau-Chonka DC, Lange LA, Smith JD, Song K, Hua ZJ, Yuan X, Luan J, Lamina C, Ziegler A, Zhang W, Zee RY, Wright AF, Witteman JC, Wilson JF, Willemssen G, Wichmann HE, Whitfield JB, Waterworth DM, Wareham NJ, Waeber G, Vollenweider P, Voight BF, Vitart V, Uitterlinden AG, Uda M, Tuomilehto J, Thompson JR, Tanaka T, Surakka I, Stringham HM, Spector TD, Soranzo N, Smit JH, Sinisalo J, Silander K, Sijbrands EJ, Scuteri A, Scott J, Schlessinger D, Sanna S, Salomaa V, Saharinen J, Sabatti C, Ruukonen A, Rudan I, Rose LM, Roberts R, Rieder M, Psaty BM, Pramstaller PP, Pichler I, Perola M, Penninx BW, Pedersen NL, Pattaro C, Parker AN, Pare G, Oostra BA, O'Donnell CJ, Nieminen MS, Nickerson DA, Montgomery GW, Meitinger T, McPherson R, McCarthy MI, McArdle W, Masson D, Martin NG, Marroni F, Mangino M, Magnusson PK, Lucas G, Luben R, Loos RJ, Lokki ML, Lettre G, Langenberg C, Launer LJ, Lakatta EG, Laaksonen R, Kyvik KO, Kronenberg F, König IR, Khaw KT, Kaprio J, Kaplan LM, Johansson A, Jarvelin MR, Cecile JWJ, Ingelsson E, Igl W, Kees HG, Hottenga JJ, Hofman A, Hicks AA, Hengstenberg C, Heid IM, Hayward C, Havulinna AS, Hastie ND, Harris TB, Haritunians T, Hall AS, Gyllensten U, Guiducci C, Groop LC, Gonzalez E, Gieger C, Freimer NB, Ferrucci L, Erdmann J, Elliott P, Ejebe KG, Döring A, Dominiczak AF, Demissie S, Deloukas P, De Geus EJ, de FU, Crawford G, Collins FS, Chen YD, Caulfield MJ, Campbell H, Burt NP, Bonnycastle LL, Boomsma DI, Boekholdt SM, Bergman RN, Barroso I, Bandinelli S, Ballantyne CM, Assimes TL, Quertermous T, Altshuler D, Seielstad M, Wong TY, Tai ES, Feranil AB, Kuzawa CW, Adair LS, Taylor HA, Jr., Borecki IB, Gabriel SB, Wilson JG, Holm H, Thorsteinsdottir U, Gudnason V, Krauss RM, Mohlke KL, Ordovas JM, Munroe PB, Kooner JS, Tall AR, Hegele RA, Kastelein JJ, Schadt EE, Rotter JJ, Boerwinkle E, Strachan DP, Mooser V, Stefansson K, Reilly MP, Samani NJ, Schunkert H, Cupples LA, Sandhu MS, Ridker PM, Rader DJ, Van Duijn CM, Peltonen L, Abecasis GR, Boehnke M, Kathiresan S: Biological, clinical and population relevance of 95 loci for blood lipids. *Nature* 466:707-713, 2010. [\[Pub-Med\]](#)

8. Heid IM\*, Henneman P\*, Hicks A\*, Coassin S, Winkler T, Aulchenko YS, Fuchsberger C, Song K, Hivert MF, Waterworth DM, Timpson NJ, Richards JB, Perry JRB, Tanaka T, Amin N, Kollerits B, Pichler I, Oostra BA, Thorand B, Frants RR, Illig T, Dupuis J, Glaser B, Spector T, Guralnik J, Egan JM, Florez JC, Evans DM, Soranzo N, Bandinelli S, Carlson OD, Frayling TM, Burling K, Davey SG, Mooser V, Ferrucci L, Meigs JB, Vollenweider P, Van Dijk KW, Pramstaller P\*, Kronenberg F\*, Van Duijn CM\*: Clear detection of *ADIPOQ* locus as the major gene for plasma adiponectin: results of genome-wide association analyses including 4659 European individuals. *Atherosclerosis* 208:412-420, 2010. [\[Pub-Med\]](#)

9. Gieger C, Geistlinger L, Altmaier E, Hrabé de Angelis M, Kronenberg F, Meitinger T, Mewes HW, Wichmann HE, Weinberger KM, Adamski J, Illig T, Suhre K: Genetics meets metabolomics: a genome-wide association study of metabolite profiles in human serum. *PLoS Genetics* 4:1000282, 2008. [\[Pub-Med\]](#)

10. Illig T, Gieger C, Zhai G, Römisch-Margl W, Wang-Sattler R, Prehn C, Altmaier E, Kastenmüller G, Kato BS, Soranzo N, Mewes HW, Meitinger T, Hrabé de Angelis M, Kronenberg F, Wichmann HE, Spector TD, Adamski J, Suhre K: A genomewide perspective of genetic variation in human metabolism. *Nature Genetics* 42:137-141, 2010. [\[Pub-Med\]](#)